Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a collaboration with the Hypertrophic Cardiomyopathy Association (HCMA), the preeminent organization improving the lives of those with hypertrophic cardiomyopathy (HCM), to support, educate and advance research for HCM.
Hypertrophic cardiomyopathy is the most commonly inherited cardiovascular disease and one of the leading causes of sudden cardiac death in people under age 35. Despite its serious nature, only 20% of the estimated one million people in the U.S. with HCM have been diagnosed. HCM causes a person’s heart muscles to thicken, making it harder for their heart to pump blood. HCM is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure.
“Thanks to our partnership with Viz.ai, we now have the opportunity to offer more support, advocacy, and education to patients, families, the medical community, and the public regarding hypertrophic cardiomyopathy,” said Lisa Salberg, Founder and CEO of the HCMA. “Together, we can enhance the lives of individuals with HCM, prevent premature deaths, and advance global understanding. There have been significant advancements in treatment options for those with HCM in recent years, and our current challenge is to identify and provide access to these new life-improving treatments for those who have been misdiagnosed or undiagnosed.”
It can take two to five years for patients to receive an HCM diagnosis after symptoms start. Viz has developed and deployed the first and only regulatory-cleared machine learning algorithm to detect signs of HCM on routine ecg’s and direct patients to the right specialists for the right treatment. Viz HCM has been shown to help expedite the process to 90 days, from initial AI-powered detection of suspected HCM to diagnosis confirmation. Viz.ai has also launched its HCM Education Series, educational webinars led by key opinion leaders, including HCM specialists and patient advocates.
“We’re thrilled to collaborate with the HCMA and have a positive impact on HCM patient care by addressing the misdiagnosis, and even, underdiagnosis of this disease and the lengthy patient journey,” said Gad Sakin, Chief Product Officer at Viz.ai. “We hope that by identifying the disease earlier, we can enable patients with HCM to have a higher quality of life and help risk stratify patients early.”
SOURCE: Businesswire